Tumor markers and treatments for Kaposi sarcoma

Lesley A. Anderson, James J. Goedert*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

4 Citations (Scopus)


Kaposi sarcoma (KS), in addition to being the most common malignancy among people with AIDS in the USA. [1], has become the most common malignancy overall in entire countries of sub-Saharan Africa [2,3]. AIDS KS prognosis has greatly improved with highly active antiretroviral therapy (HAART) [4], but this tumor is still a major cause of disfigurement, other morbidities, and mortality [4,5].

Original languageEnglish
Pages (from-to)1637-1639
Number of pages3
Issue number12
Publication statusPublished - 31 Jul 2007

Bibliographical note

We acknowledge the support offered by the Research and Development Office, Northern Ireland who funded L.A.A. in the Cancer Prevention Fellowship Program at the National Cancer Institute.


  • Africa
  • Antiviral therapy
  • Cancer chemotherapy
  • Human herpesvirus 8
  • Kaposi sarcoma
  • Transplantation
  • Virus load


Dive into the research topics of 'Tumor markers and treatments for Kaposi sarcoma'. Together they form a unique fingerprint.

Cite this